Protective Effects of Exogenous Surfactant Protein A in Allergic Rhinitis: A Mouse Model

Ren, Jie; Deng, Yuxiao; Xiao, Bokui; Wang, Guirong; Tao, Zezhang

doi:10.1177/000348941312200405

Cited by 12 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SP-A is secreted by type II alveolar epithelial cells into pulmonary surfactant, where it is involved in host defense and immune regulation by inhibiting Th2 cell differentiation, reducing Th2 cytokine levels, and increasing Th1 cytokines. It was also identified in nasal mucosa by immunostaining and PCR, and exogenous application resulted in reduced IL-4 and IL-5 levels in ovalbumin-sensitized mice [9]. These protective effects of SP-A may have therapeutic potential in allergic rhinitis.…”

Section: Nasal Mucus Proteomementioning

confidence: 88%

“…Particularly, nasal mucus proteins, major constituents and functional units of this body fluid, have not been studied extensively. Potential therapeutic targets like surfactant protein (SP-A) or clara cell protein (CC10) have been addressed in mouse models or in vitro models by analyzing their expression in the epithelium [9,10]. SP-A is secreted by type II alveolar epithelial cells into pulmonary surfactant, where it is involved in host defense and immune regulation by inhibiting Th2 cell differentiation, reducing Th2 cytokine levels, and increasing Th1 cytokines.…”

Section: Nasal Mucus Proteomementioning

confidence: 99%

See 1 more Smart Citation

Nasal mucus proteome and its involvement in allergic rhinitis

Tomazic

Darnhofer

Birner‐Gruenberger

2020

Expert Review of Proteomics

View full text Add to dashboard Cite

Introduction: Nasal mucus is the first line defense barrier against various pathogens including allergens. Proteins in nasal mucus maybe used as biomarkers for diagnosis or future therapeutic strategies. Proteomics opens the possibility to investigate whole human proteomes. Areas Covered: We aimed to analyze the existing literature on nasal mucus and nasal secretions proteomic approaches especially in allergic rhinitis. A PubMed/Medline search was conducted entering the following keywords and combinations: "nasal mucus", "nasal lavage fluid," nasal secretions," "nasal swabs," "allergic rhinitis," "proteins," and "proteomics." Expert opinion: The majority of studies focus on single proteins or protein groups mainly using ELISA techniques. Four studies met the criteria using mass spectrometry in the analysis of nasal mucus proteomes in rhinologic diseases. In these studies, 7, 35, 267, and 430 proteins were identified, respectively. These four studies are discussed in this review and put in relation to seven other proteomic studies that focus on nasal lavage fluid and nasal secretions obtained by swabs or filter paper. To put it in a nutshell, proteomics facilitates the investigation of the nasal secretome and its role in healthy and diseased state and as potential biomarkers for new diagnostic or therapeutic approaches. ARTICLE HISTORY

show abstract

Section: Nasal Mucus Proteomementioning

confidence: 88%

Section: Nasal Mucus Proteomementioning

confidence: 99%

Nasal mucus proteome and its involvement in allergic rhinitis

Tomazic

Darnhofer

Birner‐Gruenberger

2020

Expert Review of Proteomics

View full text Add to dashboard Cite

show abstract

“…In addition, research groups utilize different sensitization protocols, varying both the dosage and timing of ovalbumin administration. Some protocols administer IP doses of ovalbumin or allergen followed by intranasal challenges whereas others only give intranasal challenges . Last, the experimental techniques used to assess levels of sinonasal inflammation also vary greatly.…”

Section: Discussionmentioning

confidence: 99%

“…The primary application of using the allergic model of sinonasal inflammation is testing of novel topical or systemic drugs to reverse inflammation . In order to determine the most sensitive and reliable measure of drug efficacy, we pilot‐tested a common topical anti‐inflammatory drug used in treating CRS, budesonide, in the allergic mouse model.…”

Section: Discussionmentioning

confidence: 99%

Characterization of a novel high‐dose ovalbumin‐induced murine model of allergic sinonasal inflammation

Mendiola¹,

Tharakan²,

Chen³

et al. 2016

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

BACKGROUND Few efficacious topical therapies exist for chronic rhinosinusitis. The lack of a reproducible mouse model of CRS limits the pilot testing of potential novel anti-inflammatory therapies. Although the ovalbumin induced mouse model of sinonasal inflammation is commonly used, it is difficult to reproduce and can generate variable histologic results. In this study, we explore a variation of this model in different strains of mice and explore various inflammatory cytokines as reproducible molecular markers of inflammation. METHODS Allergic sinonasal inflammation was generated in BALB/c and C57BL/6 mice using intraperitoneal high dose injections of Ova followed by 10 days of high dose intranasal sensitization. Real-Time PCR for eotaxin, IL4, and IL13 were measured from sinonasal mucosa. We also pilot tested a known topical budesonide to characterize the anti-inflammatory response. Histological sections were analyzed for epithelial thickness and eosinophilia. RESULTS Both BALB/c and C57BL/6 mice consistently showed increases in Th2 cytokines after sensitization with high dose Ova (p<0.0001) when compared to controls. There were also significant increases in epithelial thickening in Ova sensitized mice and eosinophilia in both BALB/c and C57BL/6 strains.In addition, topical budesonide significantly reduced anti-inflammatory cytokines, eosinophilia, and epithelial thickness. CONCLUSION Our variation of the ovalbumin induced mouse model of sinonasal inflammation in both BALB/c and C57BL/6 mice provides an efficacious model for testing potential topical anti-inflammatory therapies for CRS. The utilization of sinonasal mucosal Th2 cytokines along with histologic markers provides a consistent and quantifiable marker of inflammation in assessing the efficacy of candidate drugs.

show abstract

“…L'étude de la sécrétion de SP-A dans des modèles murins a montré que l'absence de sécré-tions de SP-A entraînait en cas d'exposition allergénique une hyperéosinophilie périphérique majeure et une inflammation de type Th2 au niveau des voies aériennes [23]. En corollaire, l'administration de SP-A exogène chez des souris déficientes entraîne l'inhibition de la synthèse d'IgE spécifiques [24]. Chez l'homme, il a été montré que la sécrétion de SP-A au niveau de l'épithélium nasal était plus élevée en cas de rhinite allergique ou de polypes naso-sinusiens par rapport aux sujets sains [25,26].…”

Section: Les Protéines a Et D Du Surfactant (Sp-a Et Sp-d) Sont Des Punclassified

Les pneumoprotéines sériques, de nouveaux biomarqueurs pour phénotyper l’asthme du nourrisson ?

Fontaine¹,

Amat²,

Paluel-Marmont³

et al. 2015

Revue Française d'Allergologie

View full text Add to dashboard Cite

Il reste difficile actuellement de distinguer a priori les différents phénotypes d'asthme du nourrisson, et notamment de distinguer l'asthme à risque de persistance et de sévérité de l'asthme transitoire. Il est essentiel d'améliorer la prédiction du pronostic de l'asthme au cours de l'enfance, car l'asthme à début précoce concerne une proportion non négligeable, environ 10 %, de la population générale pédiatrique. L'épithélium pulmonaire sécrète différentes protéines, dont certaines, appelées pneumoprotéines, sont dorénavant dosables dans le sérum. Certaines d'entre elles pourraient constituer une piste intéressante dans la recherche de biomarqueurs associés aux phénotypes de l'asthme. AbstractAt present, it is still difficult to distinguish a priori different phenotypes of early-onset asthma in infants, especially to be able to differentiate infants with asthma who are at risk of persistence and severity from those with transient wheezing. It is thus essential to improve the prediction of the prognosis of early-onset asthma because of its high frequency, about 10%, in the pediatric general population. The pulmonary epithelium secretes into the serum a variety of proteins, including some known as pneumoproteins, and these proteins can now be assayed in the serum. Some of them might represent an interesting way in the search of new biomarkers associated with particular asthma phenotypes.

show abstract

Protective Effects of Exogenous Surfactant Protein A in Allergic Rhinitis: A Mouse Model

Cited by 12 publications

References 27 publications

Nasal mucus proteome and its involvement in allergic rhinitis

Nasal mucus proteome and its involvement in allergic rhinitis

Characterization of a novel high‐dose ovalbumin‐induced murine model of allergic sinonasal inflammation

Les pneumoprotéines sériques, de nouveaux biomarqueurs pour phénotyper l’asthme du nourrisson ?

Contact Info

Product

Resources

About